Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma.
Takada H, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: osawa l. Oncology. 2025;103(1):37-47. doi: 10.1159/000540648. Epub 2024 Jul 30. Oncology. 2025. PMID: 39079513
Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: osawa l. Hepatol Res. 2024 Feb;54(2):162-173. doi: 10.1111/hepr.13969. Epub 2023 Oct 6. Hepatol Res. 2024. PMID: 37740643
Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: osawa l. Oncology. 2023;101(10):655-663. doi: 10.1159/000531689. Epub 2023 Jun 28. Oncology. 2023. PMID: 37379802
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Takahashi K, Uchimura K, Enomoto N. Takada H, et al. Among authors: osawa l. Oncology. 2023;101(10):609-623. doi: 10.1159/000531111. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279708
Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Takada H, Muraoka M, Sato M, Takano S, Fukasawa M, Yamaguchi T, Funayama S, Morisaka H, Onishi H, Enomoto N. Suzuki Y, et al. Among authors: osawa l. J Gastroenterol Hepatol. 2023 Jun;38(6):921-929. doi: 10.1111/jgh.16154. Epub 2023 Mar 5. J Gastroenterol Hepatol. 2023. PMID: 36811251
Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Enomoto N. Takada H, et al. Among authors: osawa l. Oncology. 2023;101(3):173-184. doi: 10.1159/000527752. Epub 2022 Dec 14. Oncology. 2023. PMID: 36516803
43 results